Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Roche Stories

2010-05-04 06:39:00

PRINCETON, N.J., May 4 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS), in response to certain inaccuracies in an article published by PharmaWire on May 3, 2010 about its development program for treatment of hepatitis C virus (HCV) in collaboration with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd, stated today that the development of RG7128 is on track, and that no safety or other concerns have delayed the program. More specifically, M. Michelle Berrey, M.D., M.P.H.,...

2010-04-28 08:10:00

BASEL, Switzerland, April 28 /PRNewswire/ -- Roche announced today the launch of the EDUCARE (EDUcation for Cancer in African REgions) project, which, in concert with IAEA (International Atomic Energy Agency), will provide support to help combat the growing cancer epidemic in sub-Saharan Africa. The EDUCARE project is to be piloted in four African countries, and is linked with a wider initiative to build regional training networks in cancer control and a Virtual University for Cancer...

2010-04-22 13:30:00

NUTLEY, N.J., April 22 /PRNewswire/ -- Roche announced today that Mike Burgess, M.D., Ph.D., has been named Head of the Oncology Discovery and Translational Area (DTA) (1), effective immediately. The Oncology DTA is one of five disease-focused organizations at Roche, and as part of the Pharma Research and Early Development (pRED) organization, oversees research and early development up to late stage development in the field of Oncology. Most recently, Mike was Head of Academic Alliances...

2010-04-15 03:41:00

PRINCETON, N.J., April 15 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today interim efficacy and safety results from its ongoing 28-day phase 2a study with PSI-7977 dosed once daily in combination with Pegasys® (peginterferon alfa 2a) and Copegus® (ribavirin) in patients with hepatitis C virus (HCV) genotype 1 who have not been treated previously. PSI-7977 is Pharmasset's nucleotide analog for the treatment of HCV. The Company...

2010-02-09 15:00:00

PRINCETON, N.J., Feb. 9 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the fiscal quarter ended December 31, 2009. Financial Results Revenues were $0.3 million during the quarter ended December 31, 2009 compared to $0.5 million for the quarter ended December 31, 2008 and reflect...

2010-01-21 09:22:00

RESEARCH TRIANGLE PARK, N.C., Jan. 21 /PRNewswire/ -- b3 bio inc. today announced that it has signed an agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) to source and develop innovative early stage technologies that could result in potential therapeutic benefits for patients. Roche will have certain rights for further development and/or commercialization of such technologies. As part of this agreement, Roche will increase its equity investment in b3 bio as well as providing development...

2009-12-03 06:00:00

AUSTIN, Texas, Dec. 3 /PRNewswire/ -- Rules-Based Medicine, Inc. (RBM) today announced that Psynova Neurotech Limited (Cambridge UK), a majority-owned subsidiary of RBM, has executed an exclusive research and licensing agreement with Roche to collaborate on the discovery, development, validation and commercialization of diagnostic immunoassays to aid the clinical development and commercial differentiation of novel treatments for schizophrenia. Under the terms of the agreement, Roche...

2009-11-25 15:30:00

PRINCETON, N.J., Nov. 25 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, reported financial results for the fiscal year ended September 30, 2009. At September 30, 2009 Pharmasset held $58.4 million in cash, cash equivalents and short term investments. Pipeline Update and 2009 Highlights RG7128 Phase 2b Trial In late November 2009, an...

2009-11-23 05:24:00

PRINCETON, N.J., Nov. 23 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that the enrollment of Cohort 2, led by its partner Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY), will continue for the remaining 300 genotype 1 and 4 patients in the ongoing phase 2b trial of RG7128, a first-in-class nucleoside analog polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. The decision was reached after a scheduled review by an independent Data...

2009-11-12 12:53:00

INDIANAPOLIS, Nov. 12 /PRNewswire/ -- Wouldn't it be great to design a skin for your ACCU-CHEK Aviva blood glucose meter and have it end up being a future ACCU-CHEK skin offering? Chances are, you have already visited www.rockmymeter.com and tried your hand at a few skin designs. Today, Roche announced the launch of the Born in the USA Meter Skin Design Challenge, a response to high traffic to the site, along with friendly competitive spirit. "We are excited to announce this fun skin...